← Back to headlines
These 4 charts show the scale of Novo Nordisk's woes
Despite being first to launch a GLP-1 drug for weight loss, Novo's market share has eroded, and the company now only captures about 40% of the market.
25 Feb, 10:32 — 25 Feb, 10:32
ℹOnly 1 source covers this story
Related Stories
Modern Therapy for Rare Disease Available to Nine Patients in Serbia
12m ago
Michigan Mother Raises Awareness for Rare, Fatal Lafora Disease After Sons' Deaths
16m ago
Critique of the American Food System and the Role of Lunch Ladies
18m ago
Mother Charged After Cocaine Found in Three-Year-Old's Urine in Croatia
19m ago